All In Biotech

Drug Trial Radar · NCT05975021

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C

Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Actual

Start

Jun 1, 2024

Primary completion

Jul 28, 2025

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Windtree TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental status, mottled and cool extremities, and delayed capillary refill, as well as signs of congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to organs) which frequently require support with rescue therapies including inotropes, vasopressors, or mechanical devices. Windtree Therapeutics, Inc. has been studying istaroxime, which has the potential to treat patients in this condition without some of the disadvantages of existing therapies being used to treat patients with acute heart failure and CS. Participants enrolled in this trial will receive standard of care (SoC) therapy for heart failure and CS. Additionally, half of the participants will be randomly chosen to receive istaroxime. Istaroxime has the potential to increase blood pressure and improve cardiac function.

Conditions

  • Cardiogenic Shock

Interventions

  • IstaroximeDrug

    IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.

  • PlaceboDrug

    IV infusion via a syringe pump. Total duration 48 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SBP AUC 0-6Time frame: Start of infusion to 6 hours

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts

  • Oregon Health and Sciences University

    Portland, Oregon

  • Sanatorio Güemes

    Capital Federal, Buenos Aires, Argentina

  • Sanatorio De la Trinidad Palermo

    Capital Federal, Buenos Aires, Argentina

  • Instituto Cardiovascular de Rosario

    Rosario, Sante Fe, Argentina

  • Hospital Privado de Rosario

    Rosario, Sante Fe, Argentina

  • Kaplan Medical Center

    Rehovot, Israel

  • Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • IRCCS San Raffaele Scientific Institute

    Milan, Italy

  • University of Turin, Città della Salute e della Scienza

    Turin, Italy

  • Uniwersytecki Szpital Kliniczny w Białymstoku

    Bialystok, Poland

  • Uniwersytecki Szpital Kliniczny w Opolu

    Opole, Poland

  • Uniwersytecki Szpital Kliniczny, Instytut Chorob Serca

    Wroclaw, Poland

  • 4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.